Lorvotuzumab mertansine is an ADC consisting of a humanized N901 monoclonal antibody against CD56 bound to maytansinoid DM1 via a stable disulfide linker. Lorvotuzumab mertansine has antitumor activity[1].
Purity:
99.44
CAS Number:
[1008106-64-6]
Target:
Antibody-Drug Conjugates (ADCs)
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted